Ascendiant Capital Markets Has Lowered Expectations for Alzamend Neuro (NASDAQ:ALZN) Stock Price

Alzamend Neuro (NASDAQ:ALZN) had its price objective reduced by Ascendiant Capital Markets from $50.00 to $35.00 in a research note issued to investors on Monday,Benzinga reports. They currently have a buy rating on the stock.

Alzamend Neuro Stock Performance

ALZN stock opened at $1.45 on Monday. Alzamend Neuro has a twelve month low of $1.40 and a twelve month high of $19.20. The business has a 50 day moving average price of $1.69 and a two-hundred day moving average price of $3.46.

Alzamend Neuro (NASDAQ:ALZN) last released its earnings results on Wednesday, September 11th. The company reported ($1.25) earnings per share for the quarter, beating the consensus estimate of ($2.38) by $1.13. Equities research analysts forecast that Alzamend Neuro will post -14.27 EPS for the current fiscal year.

Institutional Investors Weigh In On Alzamend Neuro

A hedge fund recently bought a new stake in Alzamend Neuro stock. Virtu Financial LLC purchased a new position in shares of Alzamend Neuro, Inc. (NASDAQ:ALZN) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 26,482 shares of the company’s stock, valued at approximately $26,000. Virtu Financial LLC owned about 0.38% of Alzamend Neuro as of its most recent SEC filing. 49.61% of the stock is currently owned by institutional investors and hedge funds.

About Alzamend Neuro

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.